Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | PCTP | Q9UKL6 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13453703 | 0.92 | CA1 (0.64) | KMT2AMEN1ALDH1A1PCTPPOLB | |
| SCHEMBL13453699 | 0.91 | ALDH1A1 (0.70) | KMT2AMEN1ALDH1A1PCTPPOLB | |
| SCHEMBL13453581 | 0.86 | MEN1 (0.69) | KMT2AMEN1ALDH1A1PCTPPOLB | |
| SCHEMBL13454702 | 0.86 | ALDH1A1 (0.61) | KMT2AMEN1ALDH1A1POLBNPSR1 | |
| SCHEMBL13454476 | 0.85 | ALDH1A1 (0.63) | KMT2AMEN1ALDH1A1POLBNPSR1 | |
| SCHEMBL13454600 | 0.85 | ALDH1A1 (0.58) | KMT2AMEN1ALDH1A1GAAHPGD | |
| SCHEMBL13453629 | 0.85 | PCTP (0.73) | KMT2AMEN1ALDH1A1PCTPPOLB | |
| SCHEMBL13453684 | 0.84 | MEN1 (0.69) | KMT2AMEN1ALDH1A1PCTPPOLB | |
| SCHEMBL1235823 | 0.84 | ALDH1A1 (0.71) | KMT2AMEN1ALDH1A1PCTPPOLB | |
| SCHEMBL13453694 | 0.84 | PCTP (0.65) | KMT2AMEN1ALDH1A1PCTPPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126938-B2 | Phosphatidylcholine transfer protein inhibitors | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126938-B2 | Phosphatidylcholine transfer protein inhibitors | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20120264756-A1 | Phosphatidylcholine Transfer Protein Inhibitors | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264756-A1 | Phosphatidylcholine Transfer Protein Inhibitors | PCTP, LCAT, CETP | KMT2A 1676/4885MEN1 1940/4885ALDH1A1 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.